Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Itraconazole + YL202 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Itraconazole | Hyphanox | ITC | mTOR Inhibitor 51 | Itraconazole is an antifungal, which indirectly targets mTOR (PMID: 20176935). |
| YL202 | YL 202|YL-202|BNT326|BNT-326|BNT 326 | HER3 (ERBB3) Antibody 28 | YL202 is an antibody-drug conjugate (ADC) comprising an ERBB3 (HER3)-targeted antibody conjugated to a novel topoisomerase I inhibitor, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 563). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07070232 | Phase Ib/II | BNT327 + YL202 YL202 Itraconazole + YL202 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Recruiting | USA | GBR | AUS | 0 |